Impact Of Dupilumab on Caregiver-Reported Signs Of EOE, Using PESQ-C OVER 52 WEEKS: Results from The Phase 3 EOE Kids Study

Jonathan M. Spergel, Children's Hospital of Philadelphia, Philadelphia, PA, United States; Mirna Chehade, Mount Sinai Center for Eosinophilic Disorders, Icahn School of Medicine at Mount Sinai, New York, NY, United States; Dhandapani Ashok, Western University, London, ON, Canada; Karam Salama, Regeneron Inc, Corona, CA, United States; Changming Xia, Regeneron Pharmaceuticals Inc., Tarrytown, NY, United States; Sherif Zaghloul, Sanofi, Cambridge, MA, United States; Bram Raphael, Regeneron, Sleepy Hollow, NY, United States; James Angello, Sanofi, Bridgewater, NJ, United States; Amr Radwan, Regeneron, Tarrytown, NY, United States; Sarette T. Tilton, Sanofi, Bridgewater, NJ, United States; Ryan B. Thomas, Regeneron Pharmaceuticals Inc., Tarrytown, NY, United States